| scholarly article | Q13442814 |
| P50 | author | Raymond W. Lam | Q42883552 |
| P2093 | author name string | Michael Liebowitz | |
| Catherine Datto | |||
| Hans Eriksson | |||
| Ulla Lepola | |||
| Dennis Sweitzer | |||
| P2860 | cites work | A rating scale for depression | Q24564540 |
| Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study | Q28254377 | ||
| A rating scale for drug-induced akathisia | Q28258433 | ||
| The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research | Q29547257 | ||
| The assessment of anxiety states by rating | Q29614719 | ||
| A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
| Extrapyramidal side-effects of antipsychotics in a randomised trial | Q30492645 | ||
| Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). | Q34000973 | ||
| Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder | Q34452223 | ||
| Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial | Q34508971 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care | Q34578945 | ||
| EPS profiles: the atypical antipsychotics are not all the same | Q34605044 | ||
| Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial | Q34748493 | ||
| Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. | Q38382524 | ||
| Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study | Q38382527 | ||
| N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity | Q40039619 | ||
| Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled st | Q43153951 | ||
| Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies | Q44581952 | ||
| Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. | Q44682232 | ||
| A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression | Q46580881 | ||
| Relapse of depression in primary care. Rate and clinical predictors. | Q51991001 | ||
| Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors | Q55893215 | ||
| Sertraline in the prevention of depression | Q68064387 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | major depressive disorder | Q42844 |
| placebo | Q269829 | ||
| P304 | page(s) | 964-976 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Depression and Anxiety | Q15716773 |
| P1476 | title | Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial | |
| P478 | volume | 27 |
| Q64238308 | A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder |
| Q37299884 | A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder |
| Q37795302 | A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder |
| Q37562207 | A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder |
| Q46532995 | Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder |
| Q89842826 | Approval of esketamine for treatment-resistant depression |
| Q60923745 | Bioequivalence of two quetiapine extended release tablets in Chinese healthy volunteers under fasting and fed conditions and effects of food on pharmacokinetic profiles |
| Q38109591 | Clinical issues in use of atypical antipsychotics for depressed patients |
| Q36983421 | Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder |
| Q96162477 | Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves |
| Q36115005 | Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder |
| Q42176639 | Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission |
| Q38069670 | Eficcacy of extended release quetiapine in affective symptoms |
| Q48177790 | Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy |
| Q37299893 | Extended Release Quetiapine Fumarate (Quetiapine XR) as Adjunct Therapy in Patients with Generalized Anxiety Disorder and a History of Inadequate Treatment Response: A Randomized, Double-Blind Study |
| Q38157027 | Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy |
| Q45786962 | Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR. |
| Q26797416 | Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice |
| Q59410448 | Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review |
| Q28088645 | Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials |
| Q48086364 | Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study |
| Q21260321 | Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials |
| Q48060784 | RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND-GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY. |
| Q38350551 | Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). |
| Q28076712 | Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update |
| Q37810765 | Second-generation antipsychotics in major depressive disorder: update and clinical perspective |
| Q38125219 | Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. |
| Q30457019 | Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate |
| Q42128926 | Suicidal Risks in Report of Reports of Long-Term Treatment Trials for Major Depressive Disorder |
| Q42290223 | Suicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II. |
| Q37974998 | The hidden third: improving outcome in treatment-resistant depression |
| Q38157024 | The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder |
| Q36393992 | Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders |
| Q40149264 | Vascular endothelial growth factor: Potential predictor of treatment response in major depression |
| Q38268590 | Weight gain and antipsychotics: a drug safety review |
| Q35560309 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. |
Search more.